M/s. SUN Pharmaceuticals Morocco LL Pharmaceutical Import Profile — Morocco (DGFT 2022–2026)

Name: M/s. SUN Pharmaceuticals Morocco LL Pharmaceutical Import Records from India — 3 Products, $812.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. SUN Pharmaceuticals Morocco LL — Pharmaceutical Importer Profile (2026) | 3 Products, $812.4K Trade | TransData Nexus

M/s. SUN Pharmaceuticals Morocco LL

Pharmaceutical Importer · Morocco · Advanced Antibiotics Focus · $812.4K Total Trade · DGFT Verified

M/s. SUN Pharmaceuticals Morocco LL is a pharmaceutical importer based in Morocco with a total trade value of $812.4K across 3 products in 3 therapeutic categories. Based on 17 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. SUN Pharmaceuticals Morocco LL sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

M/s. SUN Pharmaceuticals Morocco LL — Import Portfolio & Supplier Network

M/s. SUN Pharmaceuticals Morocco LL import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. SUN Pharmaceuticals Morocco LL?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$8.0M	241	100.0%

M/s. SUN Pharmaceuticals Morocco LL sources from 1 verified Indian supplier across 172 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Flotral TAB 10MG(alfuzosin	$284.2K	7
Cilentra tabs 10MG(escitalopram	$200.0K	4
Cilentra tabs 10MG (escitalopram	$154.3K	4
Ranozyp TAB 10MG(olanzapine orodispersible tablets)Pack:4x7s batch:ptf0858a eachorodisperible TAB conts. olanzapine	$136.6K	3
Dopezil ranbaxy TAB 5MG(donepezil hydrochloride tablets)Pack:4x7s batch:pte4208ceach film coated TAB conts. donepezil	$131.3K	3
Raciper TAB 40MG(esomeprazole	$130.2K	3
Ranozyp TAB 10MG(olanzapine orodispersible tablets)Pack:4x7s batch:ptf0863b eachorodisperible tablet conts.	$129.0K	3
Memantine hydrochloride tablets	$119.8K	3
Flotral TAB 10MG ( alfuzosin	$110.3K	3
Ranciphex TAB 20MG Pack:4x7s batch:pte5558a, pte5559a, ptf0009b, ptf0489a Each gastro resistent TAB conts. rabeprazole	$107.6K	3
Contiflo od cap 0.4MG Pack:box3x10s	$100.0K	2
Dopezil ranbaxy TAB 10MG (donepezil	$100.0K	2
Ranclast injection 4MG/5ML Pack:1 vial	$100.0K	2
Anabrez 1MG TAB 2x14's (hospital	$100.0K	2
Raciper TAB 40MG(esomeprazole magnesiumgastro resistant tablets) Pack:2x7 (s07)batch:ptg1059b Each Gastro Resistant	$100.0K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Imipenem	Advanced Antibiotics	$600.0K	12	1.8%	4
2	Docetaxel	Oncology	$150.0K	3	0.4%	16
3	Topotecan	Advanced Oncology	$62.4K	2	1.7%	12

M/s. SUN Pharmaceuticals Morocco LL imports 3 pharmaceutical products across 3 categories into Morocco totaling $812.4K.

M/s. SUN Pharmaceuticals Morocco LL — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. SUN Pharmaceuticals Morocco LLC is a pharmaceutical importer based in Morocco, specializing in the procurement of finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company operates as a buyer, sourcing a diverse range of pharmaceutical products from international suppliers. While specific details about its parent company are not publicly disclosed, the name suggests a potential affiliation with Sun Pharmaceutical Industries Limited, a leading Indian multinational pharmaceutical company. This affiliation could indicate a strategic partnership or distribution agreement, enhancing SUN Pharmaceuticals Morocco LLC's access to a broad portfolio of pharmaceutical products. The company's role in Morocco's pharmaceutical distribution network involves importing and supplying a variety of pharmaceutical formulations to meet the country's healthcare needs.

2Distribution Network

Specific information regarding the warehouse locations and logistics capabilities of M/s. SUN Pharmaceuticals Morocco LLC is not publicly available. However, given the company's import activities, it is likely that it operates distribution centers within Morocco to facilitate the storage and distribution of pharmaceutical products. The geographic coverage of its distribution network would encompass major urban centers and healthcare facilities across Morocco, ensuring the availability of imported pharmaceutical products nationwide. The logistics operations are presumably designed to maintain the integrity and timely delivery of pharmaceutical goods, adhering to regulatory standards and meeting market demand.

3Industry Role

M/s. SUN Pharmaceuticals Morocco LLC functions primarily as a pharmaceutical importer, sourcing finished pharmaceutical formulations from international suppliers. Its role in Morocco's pharmaceutical supply chain is to bridge the gap between foreign manufacturers and the domestic market, ensuring the availability of a diverse range of pharmaceutical products. By importing and distributing these products, the company contributes to the enhancement of Morocco's healthcare offerings, providing access to both generic and specialty medications that may not be locally produced. This position is crucial in meeting the therapeutic needs of the Moroccan population and supporting the overall healthcare infrastructure.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. SUN Pharmaceuticals Morocco LL

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

M/s. SUN Pharmaceuticals Morocco LLC demonstrates a high degree of supplier concentration, with all its pharmaceutical imports sourced from a single supplier, SUN Pharmaceutical Industries Limited. This single-source dependency indicates a strategic choice, potentially leveraging the supplier's extensive product portfolio and established reputation. The shipment data reveals a consistent and stable relationship, with 241 shipments recorded from SUN Pharmaceutical Industries Limited, suggesting reliability and trust between the two entities. However, this concentration also presents a risk; any disruptions in the supplier's operations—such as production issues, regulatory challenges, or geopolitical events—could directly impact M/s. SUN Pharmaceuticals Morocco LLC's ability to meet market demand. Diversifying the supplier base could mitigate such risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of M/s. SUN Pharmaceuticals Morocco LLC's supply chain is closely tied to its exclusive reliance on SUN Pharmaceutical Industries Limited for pharmaceutical imports. This singular sourcing strategy may limit the company's ability to adapt to supply chain disruptions. The absence of backup suppliers and a narrow range of imported formulations could pose challenges in maintaining a steady product supply during unforeseen events. Additionally, the reliance on a single shipping route and potential exposure to regulatory changes in the supplier's country could further impact supply chain stability. To enhance resilience, the company might consider establishing relationships with multiple suppliers and diversifying its product portfolio, thereby reducing dependency on a single source and improving its capacity to navigate supply chain challenges.

Importing Pharmaceuticals into Morocco — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Morocco

1Regulatory Authority & Framework

In Morocco, the pharmaceutical sector is regulated by the Ministry of Health, which oversees the registration, quality control, and distribution of pharmaceutical products. The legal framework governing pharmaceutical imports is primarily established by Law No. 17-04 on the Code of Medicines and Pharmacy, enacted in 2006. This law outlines the procedures for the registration, manufacturing, distribution, and importation of pharmaceutical products, aiming to ensure the safety, efficacy, and quality of medicines available in the Moroccan market. The Moroccan Agency for Medicines plays a pivotal role in implementing these regulations, including issuing import authorizations and conducting inspections to maintain compliance with national and international standards.

2Import Licensing & GMP

Import licensing in Morocco requires pharmaceutical importers to obtain authorization from the Ministry of Health before bringing medicines into the country. This process involves submitting detailed documentation, including product information, manufacturing details, and proof of compliance with Good Manufacturing Practice (GMP) standards. Morocco recognizes GMP certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certificates from these recognized organizations to facilitate the importation process. Additionally, obtaining wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within Morocco, ensuring that all operations meet the regulatory requirements set forth by the Ministry of Health.

M/s. SUN Pharmaceuticals Morocco LL — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M/s. SUN Pharmaceuticals Morocco LLC's product strategy focuses on importing finished pharmaceutical formulations across three therapeutic categories: Advanced Antibiotics, Oncology, and Advanced Oncology. The substantial import value of Imipenem ($600K) indicates a strong emphasis on advanced antibiotics, addressing the critical need for effective antimicrobial treatments in Morocco. The inclusion of oncology products, such as Docetaxel ($150K) and Topotecan ($62K), reflects a strategic focus on cancer therapies, catering to the growing demand for oncology treatments in the region. This product mix suggests a commitment to providing high-quality medications in areas with significant therapeutic needs, aligning with global health priorities and the specific health challenges faced by the Moroccan population.

2Sourcing Profile

M/s. SUN Pharmaceuticals Morocco LLC's sourcing strategy is centered on importing generic pharmaceutical formulations from a single supplier, SUN Pharmaceutical Industries Limited. This approach allows the company to leverage the supplier's extensive product portfolio and established reputation in the pharmaceutical industry. The focus on generic drugs enables the company to offer cost-effective alternatives to branded medications, making essential treatments more accessible to the Moroccan market. The preference for finished formulations over active pharmaceutical ingredients (APIs) or bulk drugs indicates a strategic decision to streamline operations and ensure the availability of ready-to-use medications for distribution.

Seller's Guide — How to Become a Supplier to M/s. SUN Pharmaceuticals Morocco LL

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Moroccan market and collaborate with M/s. SUN Pharmaceuticals Morocco LLC. The company's current sourcing pattern, characterized by exclusive reliance on SUN Pharmaceutical Industries Limited, presents an opportunity for alternative suppliers to offer competitive products and terms. By providing high-quality pharmaceutical formulations and demonstrating reliability, new suppliers can position themselves as viable partners, potentially capturing a share of the Moroccan market and reducing the importer's supply chain risks. Additionally, the ongoing regulatory reforms in Morocco, such as the restructuring of pharmaceutical tariffs, may create favorable conditions for new entrants to establish partnerships and expand their market presence.

2Requirements & Qualifications

Indian exporters seeking to supply M/s. SUN Pharmaceuticals Morocco LLC

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — M/s. SUN Pharmaceuticals Morocco LL

What products does M/s. SUN Pharmaceuticals Morocco LL import from India?

M/s. SUN Pharmaceuticals Morocco LL imports 3 pharmaceutical products across 3 categories. Top imports: Imipenem ($600.0K), Docetaxel ($150.0K), Topotecan ($62.4K).

Who supplies pharmaceuticals to M/s. SUN Pharmaceuticals Morocco LL from India?

M/s. SUN Pharmaceuticals Morocco LL sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $8.0M).

What is M/s. SUN Pharmaceuticals Morocco LL's total pharmaceutical import value?

M/s. SUN Pharmaceuticals Morocco LL's total pharmaceutical import value from India is $812.4K, based on 17 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. SUN Pharmaceuticals Morocco LL focus on?

M/s. SUN Pharmaceuticals Morocco LL imports across 3 categories. The largest: Advanced Antibiotics (73.9%), Oncology (18.5%), Advanced Oncology (7.7%).

Get Full M/s. SUN Pharmaceuticals Morocco LL Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

M/s. SUN Pharmaceuticals Morocco LL

M/s. SUN Pharmaceuticals Morocco LL — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to M/s. SUN Pharmaceuticals Morocco LL?

What Formulations Does M/s. SUN Pharmaceuticals Morocco LL Import?

What Products Does M/s. SUN Pharmaceuticals Morocco LL Import?

Top Products by Import Value

M/s. SUN Pharmaceuticals Morocco LL Therapeutic Categories — 3 Specializations